These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15206129)

  • 1. [Development of a new inspection diagnostic method: genetic screening of cancer].
    Sugiyama H
    Rinsho Byori; 2004 May; 52(5):426-9. PubMed ID: 15206129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset].
    Sugiyama H
    Rinsho Byori; 2000 Feb; 48(2):155-61. PubMed ID: 10804819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?
    Bader P; Niemeyer C; Weber G; Coliva T; Rossi V; Kreyenberg H; Gerecke A; Biondi A
    Eur J Haematol; 2004 Jul; 73(1):25-8. PubMed ID: 15182334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Wilms' tumor-1 gene expression in myelodysplastic syndrome and its changes in the process of myelodysplastic syndrome transforming into acute leukemia].
    Yang JK; Li JL; Li ZG; Li ZG; Liu PJ; Li JY; Lü HR; Deng Q; Lin XM; Cao JN
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Sep; 15(9):557-9. PubMed ID: 12971856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
    Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
    J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WT1 gene expression lowered by IL-12 In vitro in peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes.
    Pan L; Zhang XJ; Niu ZY; Suo XH; Zhang JY; Yang L; Liu XJ; Qiao SK; Dong ZR; Ohno R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):501-7. PubMed ID: 16800930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wilms tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis.
    Sugiyama H
    Methods Mol Med; 2002; 68():223-37. PubMed ID: 11901505
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
    Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
    Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
    Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
    Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
    Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
    J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia.
    Sugiyama H
    Leuk Lymphoma; 1998 Jun; 30(1-2):55-61. PubMed ID: 9669676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.
    Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H
    Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
    Sugiyama H
    Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia.
    Iwasaki T; Sugisaki C; Nagata K; Takagi K; Takagi A; Kojima T; Ito M; Nakamura S; Naoe T; Murate T
    Pathol Int; 2007 Oct; 57(10):645-51. PubMed ID: 17803653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro IL-12 treatment of peripheral blood mononuclear cells from patients with leukemia or myelodysplastic syndromes: increase in cytotoxicity and reduction in WT1 gene expression.
    Pan L; Ohnishi K; Zhang WJ; Yoshida H; Maksumova L; Muratkhodjaev F; Shigeno K; Nakamura S; Luo JM; Hao HL; Fujisawa S; Naito K; Shinjo K; Takeshita A; Ohno R
    Leukemia; 2000 Sep; 14(9):1634-41. PubMed ID: 10995011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
    Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
    Sugiyama H
    Jpn J Clin Oncol; 2010 May; 40(5):377-87. PubMed ID: 20395243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
    Rosenfeld C; Cheever MA; Gaiger A
    Leukemia; 2003 Jul; 17(7):1301-12. PubMed ID: 12835718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome.
    Cilloni D; Saglio G
    Acta Haematol; 2004; 112(1-2):79-84. PubMed ID: 15179007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.